Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 9, 2008, Pages 1494-1499

  Négrier, Claude ^a   Rothschild, C ^b   Goudemand, J ^c   Borg, J Y ^d   Claeyssens, S ^e   Alessi, M C ^f   Jaffry, A C ^g   Teboul, C ^g   Padrazzi, B ^g   Waegemans, T ^g  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e CHU PURPAN   (France)

^f TIMONE HOSPITAL   (France)

^g Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

Author keywords

Afibrinogenemia; Fibrinogen concentrate; Pharmacodynamic; Pharmacokinetic; Safety

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; FIBRINOGENE T1;

ABSENCE OF SIDE EFFECTS; ADULT; AFIBRINOGENEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VITAL SIGN;

ADULT; AFIBRINOGENEMIA; AGED; AREA UNDER CURVE; FIBRINOGEN; HALF-LIFE; HUMANS; MIDDLE AGED;

EID: 49849092785     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03076.x     Document Type: Article

References (20)

1. Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29: 177-88.
2. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
3. Forbes CD. Clinical aspects of the genetic disorders of coagulation. In: Disorders of Hemostasis. Philadelphia: W.B. Saunders, 1991: 138.
4. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-52.
5. Neerman-Arbez M. The molecular basis of inherited afibrinogenaemia. Thromb Haemost 2001; 86: 154-63.
6. Neerman-Arbez M. Molecular basis of fibrinogen deficiency. Pathophysiol Haemost Thromb 2006; 35: 187-98.
7. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8: 308-21.
8. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634-7.
9. Gitlin D, Borges WH. Studies on the metabolism of fibrinogen in two patients with congenital afibrinogenemia. Blood 1953; 8: 679-86.
10. Rausen AR, Cruchaud A, McMillan CW, Gitlin D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 1961; 18: 710-16.
11. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Plasma-derived Medicinal Products. CPMP/BWP/269/95 rev3, 2001.
12. The European Agency for the Evaluation of Medicinal Products. Guideline on the Investigation of Manufacturing Processes for Plasma-derived Medicinal Products With Regard to vCJD Risk. CPMP/BWP/5136/03, 2004.
13. Flan B, Arrabal S. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: Precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol 2007; 14: 51-62.
14. The European Agency for the Evaluation of Medicinal Products. Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins. EMEA/CHMP/89249/2004, July 2005.
15. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748-56.
16. Kreuz W, Meili E, Peter-Salonen K, Dobrkovskà A, Devay J, Haertel S, Krzensk U, Egbring R. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci 2005; 32: 239-46.
17. Dengler T, Stöcker U, Kellner S, Fürst G. Chemical and immunochemical characterization of polymers of aggregates in preparations of human serum albumin. Infusionstherapie 1989; 16: 160-4.
18. Kreuz W, Meili E, Peter-Salonen K, Haertel S, Devay J, Krzensk U, Egbring R. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32: 247-53.
19. Parameswaran R, Dickinson JP, de Lord S, Keeling DM, Colvin BT. Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy. Haemophilia 2000; 6: 705-8.
20. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford A. The rare coagulation disorders -review with guidelines for management from the United Kingdom Haemophilia Centre Doctors'Organisation. Haemophilia 2004; 10: 593-628.